Molecular pathology endpoints useful for aging studies

L. J. Niedernhofer, James L Kirkland, W. Ladiges

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The first clinical trial aimed at targeting fundamental processes of aging will soon be launched (TAME: Targeting Aging with Metformin). In its wake is a robust pipeline of therapeutic interventions that have been demonstrated to extend lifespan or healthspan of preclinical models, including rapalogs, antioxidants, anti-inflammatory agents, and senolytics. This ensures that if the TAME trial is successful, numerous additional clinical trials are apt to follow. But a significant impediment to these trials remains the question of what endpoints should be measured? The design of the TAME trial very cleverly skirts around this based on the fact that there are decades of data on metformin in humans, providing unequaled clarity of what endpoints are most likely to yield a positive outcome. But for a new chemical entity, knowing what endpoints to measure remains a formidable challenge. For economy's sake, and to achieve results in a reasonable time frame, surrogate markers of lifespan and healthy aging are desperately needed. This review provides a comprehensive analysis of molecular endpoints that are currently being used as indices of age-related phenomena (. e.g., morbidity, frailty, mortality) and proposes an approach for validating and prioritizing these endpoints.

Original languageEnglish (US)
JournalAgeing Research Reviews
DOIs
StateAccepted/In press - Apr 19 2016

Fingerprint

Molecular Pathology
Metformin
Pathology
Aging of materials
Clinical Trials
Anti-Inflammatory Agents
Antioxidants
Biomarkers
Morbidity
Mortality
Pipelines
Therapeutics

Keywords

  • Aging endpoints
  • Biological age
  • Geropathology
  • Molecular pathology
  • Surrogate markers of aging
  • Translational biomarkers of aging

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Aging
  • Molecular Biology
  • Neurology

Cite this

Molecular pathology endpoints useful for aging studies. / Niedernhofer, L. J.; Kirkland, James L; Ladiges, W.

In: Ageing Research Reviews, 19.04.2016.

Research output: Contribution to journalArticle

@article{8e841acf3b514c318e54218d3ad6e30b,
title = "Molecular pathology endpoints useful for aging studies",
abstract = "The first clinical trial aimed at targeting fundamental processes of aging will soon be launched (TAME: Targeting Aging with Metformin). In its wake is a robust pipeline of therapeutic interventions that have been demonstrated to extend lifespan or healthspan of preclinical models, including rapalogs, antioxidants, anti-inflammatory agents, and senolytics. This ensures that if the TAME trial is successful, numerous additional clinical trials are apt to follow. But a significant impediment to these trials remains the question of what endpoints should be measured? The design of the TAME trial very cleverly skirts around this based on the fact that there are decades of data on metformin in humans, providing unequaled clarity of what endpoints are most likely to yield a positive outcome. But for a new chemical entity, knowing what endpoints to measure remains a formidable challenge. For economy's sake, and to achieve results in a reasonable time frame, surrogate markers of lifespan and healthy aging are desperately needed. This review provides a comprehensive analysis of molecular endpoints that are currently being used as indices of age-related phenomena (. e.g., morbidity, frailty, mortality) and proposes an approach for validating and prioritizing these endpoints.",
keywords = "Aging endpoints, Biological age, Geropathology, Molecular pathology, Surrogate markers of aging, Translational biomarkers of aging",
author = "Niedernhofer, {L. J.} and Kirkland, {James L} and W. Ladiges",
year = "2016",
month = "4",
day = "19",
doi = "10.1016/j.arr.2016.09.012",
language = "English (US)",
journal = "Ageing Research Reviews",
issn = "1568-1637",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Molecular pathology endpoints useful for aging studies

AU - Niedernhofer, L. J.

AU - Kirkland, James L

AU - Ladiges, W.

PY - 2016/4/19

Y1 - 2016/4/19

N2 - The first clinical trial aimed at targeting fundamental processes of aging will soon be launched (TAME: Targeting Aging with Metformin). In its wake is a robust pipeline of therapeutic interventions that have been demonstrated to extend lifespan or healthspan of preclinical models, including rapalogs, antioxidants, anti-inflammatory agents, and senolytics. This ensures that if the TAME trial is successful, numerous additional clinical trials are apt to follow. But a significant impediment to these trials remains the question of what endpoints should be measured? The design of the TAME trial very cleverly skirts around this based on the fact that there are decades of data on metformin in humans, providing unequaled clarity of what endpoints are most likely to yield a positive outcome. But for a new chemical entity, knowing what endpoints to measure remains a formidable challenge. For economy's sake, and to achieve results in a reasonable time frame, surrogate markers of lifespan and healthy aging are desperately needed. This review provides a comprehensive analysis of molecular endpoints that are currently being used as indices of age-related phenomena (. e.g., morbidity, frailty, mortality) and proposes an approach for validating and prioritizing these endpoints.

AB - The first clinical trial aimed at targeting fundamental processes of aging will soon be launched (TAME: Targeting Aging with Metformin). In its wake is a robust pipeline of therapeutic interventions that have been demonstrated to extend lifespan or healthspan of preclinical models, including rapalogs, antioxidants, anti-inflammatory agents, and senolytics. This ensures that if the TAME trial is successful, numerous additional clinical trials are apt to follow. But a significant impediment to these trials remains the question of what endpoints should be measured? The design of the TAME trial very cleverly skirts around this based on the fact that there are decades of data on metformin in humans, providing unequaled clarity of what endpoints are most likely to yield a positive outcome. But for a new chemical entity, knowing what endpoints to measure remains a formidable challenge. For economy's sake, and to achieve results in a reasonable time frame, surrogate markers of lifespan and healthy aging are desperately needed. This review provides a comprehensive analysis of molecular endpoints that are currently being used as indices of age-related phenomena (. e.g., morbidity, frailty, mortality) and proposes an approach for validating and prioritizing these endpoints.

KW - Aging endpoints

KW - Biological age

KW - Geropathology

KW - Molecular pathology

KW - Surrogate markers of aging

KW - Translational biomarkers of aging

UR - http://www.scopus.com/inward/record.url?scp=85008712424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008712424&partnerID=8YFLogxK

U2 - 10.1016/j.arr.2016.09.012

DO - 10.1016/j.arr.2016.09.012

M3 - Article

JO - Ageing Research Reviews

JF - Ageing Research Reviews

SN - 1568-1637

ER -